New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 12, 2014
18:39 EDTNVSPresident of Novartis Oncology Herv Hoppenot leaves company
Novartis announced that Herv Hoppenot, president of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization. Alessandro Riva, M.D., Global Head, Novartis Oncology Development and Medical Affairs, will take on the role of President of Novartis Oncology ad interim, in addition to his current role, until a successor is named in due course.
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
16:38 EDTNVSNovartis' Entresto approved by FDA for treatment of heart failure
The U.S. Food and Drug Administration today approved Entresto tablets for the treatment of heart failure. The drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure.Entresto was reviewed under the FDAs priority review program, which provides for expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over available therapy. It was also granted fast track designation, which supports FDAs efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and fill an unmet medical need.ntresto is manufactured by Novartis, based in East Hanover, New Jersey. Reference Link
08:36 EDTNVSPiper Jaffray conference call is cancelled
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
July 1, 2015
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use